



## **Enanta Pharmaceuticals Announces the Appointment of George S. Golumbeski, Ph.D. to Board of Directors**

February 11, 2014

[Download this Press Release](#)

WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 11, 2014-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the appointment of George S. Golumbeski, Ph.D., to its Board of Directors. Dr. Golumbeski will also serve as a member of the Compensation Committee and the Nominating and Corporate Governance Committees.

"Dr. Golumbeski's professional experience in business development coupled with his scientific expertise will serve Enanta well as we continue to advance our internal programs and prepare to broaden our pipeline focus," stated Jay R. Luly, Ph.D. President and Chief Executive Officer. "I look forward to his guidance and leadership on our Board."

Dr. Golumbeski has nearly 20 years' senior executive and business development experience in the pharmaceutical and biotechnology industry. Since 2009 he has served as Senior Vice President, Business Development at Celgene Corporation, a global biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases, where he is responsible for business development, M&A, licensing, and partnership activities. Prior to Celgene, he was appointed Chief Executive Officer at Nabriva Therapeutics AG, where from 2008-2009 he redirected the company's efforts and led the transition toward a development company. From 2002 to 2008, Dr. Golumbeski was Vice President, Business Development, Licensing and Strategy at Novartis-Oncology, a business unit within Novartis where he was a member of the Executive Committee which was responsible for the overall results of the business unit franchise. Previously he served as Vice President, Research and Development at Elan Biopharmaceuticals, where from 2001-2002 he was a member of the research and development management team primarily responsible for the research and development pipeline and drug candidate selection.

Earlier in his career, he held several business and corporate development positions of increasing responsibility at EMD Pharmaceuticals, Schwarz Pharma, Pierce Chemical Company and Promega Corporation.

Dr. Golumbeski received a B.A. in Biology from the University of Virginia, and a Ph.D. in Genetics from the University of Wisconsin-Madison. He completed his postdoctoral research in molecular biology at the University of Colorado-Boulder.

### **About Enanta**

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant *Staphylococcus aureus*) infections.

Source: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.  
Carol Miceli, 617-607-0710  
[cmiceli@enanta.com](mailto:cmiceli@enanta.com)